Fibrinogen Degradation Products (DR-70®)
Colorectal cancer (CRC) has decreased over the last four decades; however, it is still the second-leading cause of cancer-related death in the United States. There has been an established link between fibrinogen degradation products (FDP) and cancer. The DR-70 test measures fibrin and fibrinogen degradation products for monitoring CRC patients. This measurement detects fragments D and E along with the D-dimer that is the normal end product of fibrin cleavage by plasmin. Normal healthy individuals produce minimal amounts of FDP, but plasmin and thrombin are over-released from cancer cells which consequently increase levels. Approximately 50% of patients treated for CRC will have disease recurrence. Most FDP assays available are specific for a single FDP component. DR-70 measurement gives a larger spectrum of components. Notably, FDP can be measured in urine from bladder cancer, plasma from lung cancer, or serum from other cancers; however, serum is the specimen for this particular assay. This assay should be used in conjunction with the full clinical picture or as a monitoring aid instead of a diagnosis because some patients with cancers other than the colon can have elevated results.
- As an aid in diagnosis and treatment of colorectal cancer
- Monitoring patients who have been diagnosed previously with colorectal cancer
Increased in:
- Gastro Intestinal Disease
- Colon Cancer
- Lung Cancer
- Liver Cancer
- Breast Cancer
- Ovarian Cancer
- Cervical Cancer
- Gall Bladder Cancer
- Pancreas Cancer
- Gastric Cancer
0-1.4 µg/ml
Serum collected in serum separated tubes (SST).
Stability
- Ambient: 48 hours
- Refrigerated: 1 week
- Frozen: 3 months
- J Immunoassay Immunochem. 2010 Apr;31(2):131-47. [PMID: 20391025]
- Dis Colon Rectum. 1996; 39:1102-1106. [PMID: 8831523]
- Cancer Biomark. 2010;7(3):123-32. [PMID: 21263188]